Double maintains 3 strategies that include VKTX - Viking Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -28.16% | $416.76M | 1.43% |
TAIL | -24.99% | $87.65M | 0.59% |
VIXY | -21.41% | $195.31M | 0.85% |
CCOR | -14.80% | $64.12M | 1.18% |
IYK | -12.75% | $1.53B | 0.4% |
CARY | -11.76% | $347.36M | 0.8% |
BSMR | -11.64% | $235.44M | 0.18% |
XLP | -10.29% | $16.87B | 0.09% |
IBTG | -10.14% | $1.82B | 0.07% |
USDU | -9.08% | $206.96M | 0.5% |
MMIN | -7.39% | $473.48M | 0.3% |
LGOV | -7.32% | $664.16M | 0.67% |
AGZ | -7.00% | $644.13M | 0.2% |
BSMW | -6.99% | $101.29M | 0.18% |
FSTA | -6.90% | $1.30B | 0.084% |
CTA | -6.68% | $978.30M | 0.76% |
FTXG | -6.65% | $26.06M | 0.6% |
VDC | -6.54% | $7.46B | 0.09% |
GOVZ | -6.54% | $296.64M | 0.1% |
FXY | -6.34% | $549.84M | 0.4% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ALT | 39.87% | $368.13M | -48.55% | 0.00% |
KRYS | 39.50% | $5.21B | +1.76% | 0.00% |
CRNX | 37.66% | $2.92B | -34.08% | 0.00% |
PLXS | 37.43% | $3.52B | +34.50% | 0.00% |
NOW | 36.81% | $170.74B | +8.55% | 0.00% |
GPCR | 36.57% | $971.01M | -57.69% | 0.00% |
BELFB | 36.42% | $929.63M | +24.17% | 0.41% |
LTM | 35.78% | $9.43B | -100.00% | <0.01% |
ROIV | 35.48% | $7.19B | -12.42% | 0.00% |
PEGA | 34.59% | $6.20B | +16.23% | 0.18% |
CLDX | 34.49% | $1.15B | -56.93% | 0.00% |
DNLI | 34.12% | $2.00B | -29.07% | 0.00% |
WH | 33.60% | $7.17B | +24.90% | 1.78% |
APH | 33.60% | $82.28B | +17.71% | 0.97% |
CIGI | 33.52% | $6.28B | +3.65% | 0.25% |
TYL | 33.42% | $25.08B | +40.18% | 0.00% |
CMPS | 33.12% | $211.83M | -68.14% | 0.00% |
LGND | 32.92% | $2.09B | +45.50% | 0.00% |
PRTA | 32.37% | $653.46M | -49.96% | 0.00% |
OCUL | 32.24% | $1.17B | -13.14% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
MUNI | -0.04% | $1.83B | 0.35% |
TIP | 0.05% | $14.58B | 0.18% |
STPZ | -0.05% | $427.83M | 0.2% |
VTEB | -0.12% | $36.03B | 0.03% |
SPAB | 0.13% | $8.34B | 0.03% |
BBAG | 0.15% | $1.09B | 0.03% |
TDTF | 0.17% | $773.89M | 0.18% |
CGSM | 0.17% | $640.07M | 0.25% |
TPMN | 0.20% | $33.32M | 0.65% |
MBB | 0.22% | $36.84B | 0.04% |
ITM | -0.23% | $1.90B | 0.18% |
AGG | -0.25% | $124.99B | 0.03% |
IUSB | 0.26% | $33.05B | 0.06% |
MLN | -0.27% | $534.56M | 0.24% |
FBND | -0.28% | $18.68B | 0.36% |
TAXF | -0.28% | $517.32M | 0.29% |
BIV | -0.29% | $22.32B | 0.03% |
FISR | -0.36% | $324.68M | 0.5% |
MUB | -0.38% | $39.67B | 0.05% |
JPLD | 0.40% | $1.15B | 0.24% |
SeekingAlpha
Bumbershoot had over 10+ companies drop more than -15% in Dec. 2024. So, why does Bumbershoot actually believe 2024 was a solid year? Find out.
Yahoo
Here are two great examples in the biotech industry: Viking Therapeutics (NASDAQ: VKTX) and Exelixis (NASDAQ: EXEL). Viking Therapeutics, a mid-cap biotech, is looking to make waves in the fast-growing market for weight management medicines. It will move forward with phase 3 studies for this product soon.
Yahoo
Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight loss drugs yet, but it could be on the way. The biotech is studying injectable and oral formulations of VK2735 in clinical trials, and results so far have been impressive.
Yahoo
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $23.91, marking a -0.99% move from the previous day.
Yahoo
Viking Therapeutics (NasdaqCM:VKTX) has experienced an 11% monthly decline in its stock price, a notable movement amid its recent announcements and a wider market downturn. The company completed the enrollment for its Phase 2 trial of VK2735, a dual agonist targeting obesity, and entered a significant manufacturing agreement with CordenPharma, focusing on securing long-term supply. Despite these advancements, market-wide apprehension over upcoming tariffs, coupled with a selloff impacting...
Yahoo
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BBY | <0.01% | $16.01B | -4.51% | 5.87% |
IMAB | -0.01% | $59.95M | -57.47% | 0.00% |
GOOS | -0.02% | $827.10M | -29.29% | 0.00% |
STZ | 0.03% | $33.02B | -31.55% | 2.23% |
NUS | -0.04% | $354.52M | -44.69% | 3.52% |
TFX | -0.05% | $6.56B | -34.16% | 0.98% |
XIFR | 0.06% | $869.87M | -67.92% | 29.95% |
COKE | -0.07% | $12.20B | +72.27% | 0.44% |
TAK | -0.08% | $47.49B | +10.72% | 2.14% |
AVA | -0.08% | $3.41B | +22.42% | 4.51% |
ARRY | 0.09% | $750.95M | -65.69% | 0.00% |
V | 0.10% | $676.58B | +25.05% | 0.65% |
BRK.B | 0.10% | $1.16T | +27.96% | 0.00% |
HCA | -0.10% | $85.44B | +4.46% | 0.77% |
DIS | -0.11% | $176.95B | -17.73% | 1.04% |
ATUS | 0.12% | $1.22B | +1.54% | 0.00% |
PARAA | 0.13% | $15.13B | +2.22% | 0.89% |
CIG.C | -0.13% | $2.35B | +14.03% | 0.00% |
VRSN | -0.13% | $24.17B | +35.21% | 0.00% |
NOMD | 0.14% | $3.02B | +4.08% | 3.10% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 50.66% | $4.76B | 0.35% |
IBB | 39.74% | $5.61B | 0.45% |
PBE | 39.57% | $224.98M | 0.58% |
PINK | 36.22% | $138.92M | 0.5% |
PTH | 35.26% | $107.91M | 0.6% |
FXL | 34.99% | $1.19B | 0.62% |
SECT | 34.88% | $1.83B | 0.78% |
IWO | 34.57% | $10.72B | 0.24% |
TECB | 34.33% | $383.14M | 0.3% |
IWC | 34.20% | $797.08M | 0.6% |
ONEQ | 34.07% | $6.81B | 0.21% |
VGT | 33.81% | $76.20B | 0.09% |
ROBT | 33.79% | $420.42M | 0.65% |
VBK | 33.75% | $17.32B | 0.07% |
JGRO | 33.75% | $4.86B | 0.44% |
WTAI | 33.71% | $168.60M | 0.45% |
FBT | 33.71% | $1.08B | 0.56% |
IYW | 33.53% | $17.75B | 0.39% |
IGM | 33.45% | $5.25B | 0.41% |
CGGR | 33.43% | $10.05B | 0.39% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ROL | -22.93% | $26.55B | +20.37% | 1.13% |
EW | -19.65% | $42.20B | -22.54% | 0.00% |
WM | -19.16% | $94.32B | +11.47% | 1.30% |
LKQ | -18.83% | $11.22B | -16.85% | 2.88% |
PM | -15.11% | $242.82B | +71.62% | 3.29% |
WTRG | -14.29% | $10.85B | +9.33% | 3.12% |
SUI | -13.57% | $16.45B | +4.99% | 2.87% |
HIHO | -13.27% | $7.92M | -15.09% | 6.67% |
RSG | -13.17% | $76.45B | +29.37% | 0.92% |
PG | -12.98% | $397.45B | +8.55% | 2.32% |
EXC | -12.87% | $46.41B | +23.54% | 3.25% |
MDLZ | -12.84% | $85.54B | -2.71% | 2.67% |
WEC | -12.68% | $34.37B | +34.01% | 3.09% |
CME | -12.63% | $94.61B | +23.82% | 3.89% |
AEP | -12.46% | $57.54B | +27.77% | 3.31% |
KO | -12.40% | $306.97B | +19.22% | 2.66% |
CHD | -12.17% | $26.66B | +5.00% | 1.03% |
PULM | -11.83% | $22.13M | +234.81% | 0.00% |
TSN | -11.70% | $21.91B | +8.55% | 3.09% |
INVH | -11.68% | $21.22B | -0.32% | 3.31% |
Current Value
$24.441 Year Return
Current Value
$24.441 Year Return